Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532090 | 0.81 | NAMPT (0.76) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15530942 | 0.80 | NAMPT (0.73) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15531840 | 0.79 | NAMPT (0.78) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15531096 | 0.79 | NAMPT (0.82) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL16227758 | 0.79 | NAMPT (0.82) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15531842 | 0.79 | NAMPT (0.73) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15531778 | 0.77 | NAMPT (0.76) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15533349 | 0.77 | NAMPT (0.74) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL16227562 | 0.77 | NAMPT (0.64) | NAMPTHDAC1HDAC3NCOR1HDAC4 | |
| SCHEMBL15533937 | 0.77 | NAMPT (0.73) | NAMPTHDAC1HDAC3NCOR1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193209-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9334264-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2850081-A1 | THIAZOLECARBOXAMIDE DERIVATIVES FOR USE AS NAMPT INHIBITORS | AbbVie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20140336167-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2013170118-A1 | THIAZOLECARBOXAMIDE DERIVATIVES FOR USE AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336167-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885HDAC1 56/4885HDAC3 100/4885 |
| US-20160193209-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885HDAC1 56/4885HDAC3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.